Related Experiment Video
Updated: Jun 6, 2025

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
Aortic valve sclerosis is not a benign finding but progressive disease associated with poor cardiovascular outcomes
Jeong Hun Seo1, Kwang Jin Chun1, Bong-Ki Lee1
1Division of Cardiology, Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Republic of Korea.
Insights
Aortic valve sclerosis progression significantly increases cardiovascular mortality risk. Monitoring patients with AVS progression is crucial for better cardiovascular outcomes.
Area of Science:
- Cardiology
- Echocardiography
- Vascular Biology
Background:
- Aortic valve sclerosis (AVS) shares atherosclerosis risk factors.
- The link between AVS progression and cardiovascular (CV) risk is under-researched.
Purpose of the Study:
- To investigate cardiovascular outcomes in patients based on AVS progression.
- To identify predictors of AVS progression.
Main Methods:
- Included 2,901 patients with AVS and serial echocardiograms (≥1 year apart).
- Defined primary outcome as CV death, myocardial infarction, stroke, or revascularization.
- Analyzed predictors of AVS progression using stepwise regression.
Main Results:
- 15.1% of AVS patients progressed to aortic stenosis over a median of 3.9 years.
- AVS progression was associated with older age, atrial fibrillation, peripheral artery disease, and increased left ventricular mass index.
- Patients with AVS progression had significantly higher rates of adverse CV events (P < 0.0001).
- AVS progression was an independent predictor of CV mortality (HR, 1.33; 95% CI, 1.10-1.61).
Conclusions:
- AVS progression is an independent risk factor for cardiovascular mortality.
- Patients with AVS progression may benefit from intensified cardiovascular risk management and monitoring.
Background:
Aortic valve sclerosis (AVS) shares risk factors with atherosclerosis. However, the relationship between AVS progression with cardiovascular (CV) risk has not been researched. This study investigates CV outcomes according to progression of AVS.
Methods:
This study included 2,901 patients with AVS (irregular leaflet thickening and peak aortic jet velocity < 2 m/sec) who underwent serial echocardiograms at least 1 year apart during 2011-2020. The primary outcome was defined as CV death, myocardial infarction, stroke, or revascularization.
Results:
During a median follow-up period of 3.9 years, 439 of 2,901 AVS patients (15.1%) progressed to mild or greater aortic stenosis. Patients with progression were older and more likely to have atrial fibrillation than those without. In a stepwise regression, age (odds ratio [OR] per 1-year increase, 1.04; 95% confidence interval [CI], 1.01-1.07), peripheral artery disease (OR, 9.07; 95% CI, 3.12-26.4), and left ventricular mass index (OR per 1-g/m2 increase, 1.01; 95% CI, 1.00-1.02) were associated with AVS progression. Over a median of 6.3 years, the primary outcome occurred in 858 of 2,901 patients (29.6%). Patients with progression had higher frequency of CV death, myocardial infarction, stroke, or revascularization than those without progression (P < 0.0001). In Cox proportional hazards regression, AVS progression (hazard ratio, 1.33; 95% CI, 1.10-1.61) was a significant determinant of CV mortality.
Conclusions:
The progression to aortic stenosis in AVS patients is an independent risk factor for CV mortality. These findings suggest that patients with AVS progression may benefit from stricter CV risk monitoring.
Related Concept Videos
Mitral Stenosis I: Introduction
Aortic Regurgitation I: Introduction
Rheumatic Heart Disease I: Introduction
Mitral Regurgitation I: Introduction
Mitral Valve Prolapse I: Introduction
Aortic Regurgitation IV: Nursing Management

